Aktienanalyse zu Kiora Pharmaceuticals Inc (KPRX)KPRXKiora Pharmaceuticals Inc

Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing and commercializing therapies for the treatment of retinal diseases. The Company is engaged in developing KIO-301, a vision-restoring small molecule that acts as a photoswitch specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). It is also developing KIO-104 for the treatment of retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-104 is a non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) formulated for intravitreal delivery and is ideally suited to suppressing overactive T-cell activity to treat the underlying inflammation. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Kiora Pharmaceuticals Inc is not a good buy right now. The stock is currently priced at $1.41, which is significantly below its 52-week high of $2.91, indicating a substantial decline. The RSI is at a very low 19.17, suggesting that the stock is oversold, but this could also indicate persistent weakness. Additionally, the forward P/E ratio is 2.41, which might seem attractive, but the company has reported consistent losses, including a Q1 loss of $0.58 per share and a net income of -$2,417,984 for Q1 2026. The main risk is the high volatility and lack of profitability, as evidenced by a 20-day change of -44.49%.